LIVNLivaNova PLC

$3B

Q2 2024 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$319M+8.4% YoY

Gross Profit

$215M67.4% margin

Operating Income

$40M12.6% margin

Net Income

$16M5.1% margin

EPS (Diluted)

$0.30

QoQ Revenue Growth

+8.0%

Cash Flow

Operating Cash Flow

$43M

Free Cash Flow

$31M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$2.5B

Total Liabilities

$1.2B

Stockholders' Equity

$1.2B

Cash & Equivalents

$329M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$319M	$294M	+8.4%
Gross Profit	$215M	$205M	+4.7%
Operating Income	$40M	$17M	+131.2%
Net Income	$16M	$1M	+1314.1%

Revenue Segments

Cardiopulmonary Segment

$174M55%

Neuromodulation Segment

$143M45%

Geographic Segments

UNITED STATES

$180M56%

Locations Excluding The United States And Europe

$88M28%

Europe

$51M16%

LIVN Q2 2024 Earnings — LivaNova PLC Revenue & Financial Results | Market Cap Arena